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EDITORIAL
Fatigued muscles in COPD but no finishing line in sight
H.R. Gosker and A.M.W.J. Schols
D
ecreased exercise capacity is a prominent symptom
leading to progressive disablement in chronic obstruc-
tive pulmonary disease (COPD). Exercise capacity is
frequently measured by means of incremental cycle ergometry.
Although a well-established test, studies are ongoing to
improve test design, test variables and data interpretation.
For example, a high-intensity constant-work rate cycle erg-
ometer test appears to be more informative than an incre-
mental test to evaluate the outcome of rehabilitative
interventions. At present, however, incremental cycle ergome-
try is considered the gold standard for evaluating the
pathophysiology of exercise impairment in COPD [1].
Besides decreased ventilatory function, skeletal muscle dys-
function has been identified as an important determinant of
exercise limitation in moderate-to-severe COPD. Impaired
muscle function can manifest itself as the loss of strength
and/or as reduced endurance (i.e. fatigue). Both are obviously
involved in COPD but their relative contribution to exercise
intolerance in individual patients is as yet unclear. In healthy
subjects as well as in COPD patients, muscle strength depends
largely on muscle mass or fat-free mass; fat-free mass has indeed
been found to be a strong predictor of exercise capacity [2].
However, the relationship between fat-free mass (i.e. muscle
strength) and exercise capacity was much weaker in COPD
patients as compared with healthy controls, which may point to
a more prominent role for muscle fatigue in COPD.
But how to proceed? First of all, there is an urgent need for
adequate muscle function tests and reference values. The
determination of muscle fatigue, however, is very complicated
since there is no uniform definition of muscle fatigue and
available tests are not comparable.
FUNCTIONAL ASSESSMENT OF MUSCLE FATIGUE
Muscle fatigue can be defined as the reversible loss of muscle
force due to work over time. Several studies have implemented
this concept to evaluate leg muscle fatigue in COPD. Some
measured the decrease in maximal force over a sustained
isometric contraction [3] or in a series of isokinetic maximal
voluntary contractions [2]. These tests are powerful (maximal
contractions) and of rather short duration (,1 m). Exercise
protocols of longer duration (,2–15 min) have also been
applied: the duration and work of a series of dynamic
submaximal voluntary contractions until exhaustion [4]; the
drop in involuntary muscle force measured by magnetic
stimulation pre- and post-whole body [5, 6] or single leg [7]
fatiguing tasks; electromyogram analysis during cycling
exercise [6, 8]; and the fall in maximal twitch force during
repetitive magnetic stimulation [9]. Subjective leg fatigue has
also been evaluated, mostly by comparing pre- and post-
exercise Borg or visual analogue scale scores [6, 10]. The large
diversity in the nature of these exercises, such as variations in
duration, intensity and stimulation frequency, is likely to result
in different kinds of muscle fatigue. For example, short
extensive exercise muscle contractions depend highly on the
fast-twitch muscle fibres, the phosphocreatine buffer and
glycolytic metabolism, whereas prolonged exercise depends
more on slow-twitch fibres and oxidative metabolism.
METABOLIC ASSESSMENT OF MUSCLE FATIGUE
Reduced muscle endurance in COPD occurs independently of
the loss of muscle mass; its origin must therefore be sought in
the intrinsic muscular alterations, such as reduced fibre type I
proportion and decreased oxidative enzyme activities [2]. In vivo
studies using noninvasive 31P-nuclear magnetic resonance
revealed that muscular levels of high-energy phosphates (e.g.
adenosine triphosphate (ATP), phospocreatine and reduced
nicotinamide adenine dinucleotide) are reduced at rest and that
their rephosphorylation during and after physical exercise is
slower in COPD patients as compared with healthy control
subjects, indicative of impaired oxidative energy metabolism.
As oxidative phosphorylation of adenosine diphosphate (ADP)
to produce ATP fails to meet the energy demand, the muscle cell
switches to anaerobic metabolism resulting in the formation of
lactate. Elevated blood lactate during exercise is frequently used
to monitor muscle fatigue during cycle ergometry, and in COPD
an early onset of the lactate threshold has indeed been
associated with reduced muscle oxidative capacity [11].
Another marker to monitor the onset of muscle fatigue is blood
ammonia, which normally closely follows the lactate response
during exercise. As muscle ATP consumption exceeds ATP
supply, the ATP/ADP ratio drops, impairing the functions of the
primary ATP consumers in the muscle (myosin adenosine
triphosphatase (70%) and sarcoplasmic reticulum ATPase
(25%)), leading to the loss of muscle contractility (i.e. fatigue).
To maintain the ATP/ADP ratio the enzyme adenylate kinase
transfers an energy-rich phosphate group from one ADP to
another ADP, resulting in one ATP and one adenosine
monophosphate (AMP) molecule. AMP is subsequently
degraded to inosine monophosphate (IMP) and ammonia by
the enzyme AMP deaminase [12]. CALVERT et al. [13] were the
first to study ammonia levels during cycle ergometry in COPD.
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In this study presented in the current issue of the European
Respiratory Journal, they found that, compared with healthy
controls, ,60% of the COPD patients exhibited a rise in blood
ammonia associated with a rise in intramuscular IMP levels
during cycle exercise, despite a lower absolute work load. This
implies that the relative ammonia production is higher in these
patients, which in turn suggests that enhanced AMP degradation
as a consequence of insufficient ATP production to meet energy
demands occurred. This finding fits with the reduced muscle
oxidative phenotype of COPD patients. In addition, hydrogen
peroxide is formed by the enzyme xanthine oxidase in the
further degradation of IMP into uric acid, which may lead to loss
of muscle contractility and thus augment muscle fatigue [14].
Remarkably, in the study by CALVERT et al. [13], a clear ammonia
response was absent in nine out of 24 (, 40%) COPD patients
during incremental cycling. As AMP deaminase activity is
predominant in glycolytic type II fibres, CALVERT et al. [13]
suggested that the I to II fibre type shift, which has consistently
been reported for COPD, might not be present in this particular
subgroup of patients. However, this is unlikely as it would imply
that muscle fibre type distribution resembles that of the healthy
controls who did show a rise in ammonia. An alternative,
although very speculative, explanation could be a bias introduced
through use of b2-adrenoreceptor agonists prior to the exercise
test, since it has been shown that acute administration of these
drugs decreases blood ammonia levels during exercise in healthy
subjects [15]. A more plausible explanation, also provided by
CALVERT et al. [13], is that ATP supply met ATP demand during
exercise in this subgroup. It has indeed been shown that for
cycling, ,40% of the COPD patients specified dyspnoea as a
limiting factor [16], indicating that the leg muscles may not yet
have reached their fatigue threshold. However, the fact that blood
lactate increased despite the absence of the rise in blood ammonia
in these patients suggests otherwise. Another explanation for the
absence of the ammonia response could relate to an abnormal
protein metabolic response after exercise. ENGELEN et al. [17]
reported that, in contrast to healthy control subjects, protein
turnover did not show the expected increase during cycle
exercise in a subgroup of COPD patients.
For a better understanding of muscle fatigue in chronic
obstructive pulmonary disease it is crucial to validate the
functional and metabolic indices of fatigue against each other.
For example, muscle fatigue was found to be associated with
reduced muscle oxidative capacity and slow-fibre type propor-
tions in the repetitive magnetic stimulation test mentioned
previously [9]. It would be interesting to also measure lactate
and/or ammonia kinetics during this test, as it would tell us
whether this is a similar fatigue to that which occurs during the
cycle ergometry tests. With this approach the nature and relative
contribution of muscle fatigue to exercise intolerance in chronic
obstructive pulmonary disease can be identified. Only then will
the finishing line for fatigued muscles be in sight and the next
challenge can then be undertaken to improve muscle perfor-
mance: individually tailored intervention strategies.
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